ClinicalTrials.gg
CompletedNCT06762600Updated Apr 30, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

A Phase 1 interventional study of HRS-4729 injection and HRS-4729 injection placebo in Overweight or Obesity, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.

Enrollment
11th of 16
102 · median 142
Started
2025
with 7 others
Phase 1
5 of 16
1 open now
Registered
6th of 16
by date
Lead sponsor
9 of 16
Fujian Shengdi Pharmaceutical Co., Ltd.

Among the 16 studies testing ribupatide in Obesity, this one is the 11th largest by enrollment, is one of 8 that started in 2025, is one of 5 in phase 1, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ribupatide in Obesity, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-4729 injection in healthy subjects.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 102 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily provides written prior to the initiation of any study-related activities and demonstrates understanding of the procedures and methods involved in the study, agreeing to adhere strictly to the clinical trial protocol to complete the study.
  2. Male or female subjects; aged 18 to 55 years.
  3. Self-reports no more than a 5 kg change in body weight during the 3 months prior to screening (including the screening visit).

Exclusion criteria

Exclusion Criteria:

  1. A history of current significant disease in the neurological, psychiatric, cardiovascular, gastrointestinal, respiratory, genitourinary, endocrine, hematologic, or immune systems, as determined by the investigator, which would render the subject unsuitable for participation in this trial.
  2. A history of significant gastrointestinal disease or related symptoms, conditions affecting gastric emptying, or prior gastrointestinal surgery.
  3. Subjects who have had a major surgery or severe trauma within 6 months prior to screening, or who are planned for surgical procedures during the trial period.
  4. Participation in any drug or medical device clinical trial within 3 months prior to screening.
  5. Any abnormal physical examination, vital signs, laboratory tests, chest X-ray and abdominal ultrasound findings deemed by the investigator, rendering the subject unsuitable for participation.
  6. Clinically significant abnormalities on 12-lead as determined by the investigator.
  7. Known or suspected history of drug abuse or substance dependence, or positive urine drug screen during the screening period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Treatment group 1

    Drug: HRS-4729 injection · Drug: Acetaminophen

  • Placebo comparator
    Treatment group 2

    Drug: HRS-4729 injection placebo · Drug: Acetaminophen

  • Experimental
    Treatment group 3

    Drug: HRS9531 injection

  • Placebo comparator
    Treatment group 4

    Drug: HRS9531 injection placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: Screening period up to day 43.

Secondary outcomes

  1. The maximum plasma concentration (Cmax)

    Time frame: Post-dose at day 1 to day 43.

  2. Time to maximum plasma concentration (Tmax)

    Time frame: Post-dose at day 1 to day 43.

  3. Terminal half-life (t1/2)

    Time frame: Post-dose at day 1 to day 43.

  4. Apparent clearance (CL/F)

    Time frame: Post-dose at day 1 to day 43.

  5. Apparent volume of distribution (Vz/F)

    Time frame: Post-dose at day 1 to day 43.

  6. Anti-HRS-4729 antibodies

    Time frame: Post-dose at day 1 to day 43.

  7. Changes from baseline in Fasting Body Weight

    Time frame: Run-in Period up to Day 113.

  8. Changes from baseline in Fasting Plasma Glucose

    Time frame: Run-in Period up to Day 113.

  9. Changes from baseline in Fasting Insulin

    Time frame: Run-in Period up to Day 113.

  10. Changes from baseline in Fasting C-Peptide

    Time frame: Run-in Period up to Day 113.

  11. Total fat mass

    Time frame: Run-in Period up to Day 113.

08

Study locations

1 site
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Mar 2026, 13 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 13 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2024
First posted
Jan 7, 2025
StartActual
Jan 16, 2025
Primary completionActual
Mar 12, 2026
CompletionActual
Mar 12, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06762600
Responsible party
Sponsor
First posted
Jan 7, 2025
Start date
Jan 16, 2025
Primary completion
Mar 12, 2026
Completion
Mar 12, 2026
Last update
Apr 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-4729 · Ribupatide · Acetaminophen

Start the discussion